DDInter856 DDInter1508
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.
Prasugrel {u} (Compound) binds {v} (Gene) P2RY12
Prasugrel {u} (Compound) is included by {v} (Pharmacologic Class) P2Y12 Receptor Antagonists
Prasugrel {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Prasugrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Prasugrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexlansoprazole
Prasugrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Milnacipran
Prasugrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vortioxetine
Prasugrel {u} may lead to a major life threatening interaction when taken with {v} Dipyridamole
Prasugrel {u} may lead to a major life threatening interaction when taken with {v} Dalteparin
Prasugrel {u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v} Clopidogrel
Prasugrel (Compound) binds P2RY12 (Gene)
Prasugrel (Compound) is included by P2Y12 Receptor Antagonists (Pharmacologic Class)
Prasugrel (Compound) causes Hypersensitivity (Side Effect)
Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Prasugrel may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Prasugrel may lead to a major life threatening interaction when taken with Dipyridamole
Prasugrel may lead to a major life threatening interaction when taken with Dalteparin
Prasugrel (Compound) resembles Clopidogrel (Compound) and Prasugrel may lead to a major life threatening interaction when taken with Clopidogrel